Fcpm III Services B.V. reported 10 positions worth $749.58M for the quarter ended Jun 30, 2026, up 4.8% on the prior quarter. It opened 1 new position, added to 0, trimmed 2 and exited 0. Its largest holding is NewAmsterdam Pharma Co N.V. at 38.4% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| AURA Aura Biosciences, Inc. | +4.05M | – | $28.78M | 3.84% |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| AURA Aura Biosciences, Inc. | +4.05M | $28.78M | 3.84% |
No positions were closed this quarter.
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | NAMS NewAmsterdam Pharma Co N.V. | Healthcare | 8.49M | $287.74M | 38.39% | -708.5K | -7.7% | Reduced | 6.88% |
| 2 | MPLT MapLight Therapeutics, Inc. | Healthcare | 3.23M | $115.63M | 15.43% | 0 | 0.0% | Unchanged | 7.1% |
| 3 | DYN Dyne Therapeutics, Inc. | Healthcare | 3.85M | $85.47M | 11.4% | -796.1K | -17.1% | Reduced | 2.32% |
| 4 | VOR Vor Biopharma Inc. | Healthcare | 4.12M | $75.80M | 10.11% | 0 | 0.0% | Unchanged | 7.56% |
| 5 | DMRA Damora Therapeutics, Inc. | Healthcare | 2.44M | $63.49M | 8.47% | 0 | 0.0% | Unchanged | 3.95% |
| 6 | REPL Replimune Group, Inc. | Healthcare | 2.81M | $31.09M | 4.15% | 0 | 0.0% | Unchanged | 2.9% |
| 7 | CBIO Crescent Biopharma, Inc. | Healthcare | 1.68M | $30.20M | 4.03% | 0 | 0.0% | Unchanged | 5.5% |
| 8 | AURA Aura Biosciences, Inc. | Healthcare | 4.05M | $28.78M | 3.84% | +4.05M | – | New | 3.92% |
| 9 | ENGN enGene Therapeutics Inc. | Healthcare | 9.63M | $16.66M | 2.22% | 0 | 0.0% | Unchanged | 13.82% |
| 10 | BCYC Bicycle Therapeutics Plc | Healthcare | 3.47M | $14.71M | 1.96% | 0 | 0.0% | Unchanged | 4.97% |
Tip. Select a row to see that position’s full history at Fcpm Iii Services B.V.
As of its Q2 2026 13F filing, Fcpm III Services B.V.’s five largest positions were NewAmsterdam Pharma Co N.V. (NAMS) at 38.4%, MapLight Therapeutics, Inc. (MPLT) at 15.4%, Dyne Therapeutics, Inc. (DYN) at 11.4%, Vor Biopharma Inc. (VOR) at 10.1%, Damora Therapeutics, Inc. (DMRA) at 8.5% of the reported portfolio.
Fcpm III Services B.V. reported a 13F portfolio worth $749.58M across 10 positions for Q2 2026. That is up 4.8% from the previous quarter.
Its largest purchases by value were Aura Biosciences, Inc. ($28.78M). It opened 1 new positions.
Its largest sales by value were NewAmsterdam Pharma Co N.V. ($24.01M), Dyne Therapeutics, Inc. ($17.68M). It exited 0 positions entirely.
From the Form 13F-HR reports Fcpm III Services B.V. files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.